

Special Issue

Emerging Trends in Immunotherapy for Triple Negative Breast Cancer

Message from the Guest Editor

This Special Issue aims to highlight the basic, translational, and clinical research advancements addressing these concerns in TNBC immunotherapy to improve therapy responses and promote favorable outcome in patients. In this special issue we are inviting original articles/focused reviews on the following research topics:

Novel biomarkers or targets of single and combination immunotherapies.

Immunotherapeutic developments but not limited to Immune checkpoint inhibitors (ICI), antibodies (monoclonal or bispecific), combination therapy, antibody-drug conjugates, CAR-T, CAR-M or CAR-NK based immunotherapies, neoantigen cancer vaccine, mRNA vaccine.

Cytokine and cytokine receptor mediated immunotherapy.

Molecular mechanisms of response and resistance to immunotherapy and strategies to overcome immunotherapy resistance.

Metabolic markers for immunotherapy.

Utility of TILs based immunotherapy- assessment, prognostic value and challenges.

Impact of immunotherapy on fertility of pre-menopausal women with TNBC.

Impact of immunotherapy on breast cancer tumor microenvironment (tumor-immune cell interactions).

Guest Editor

Dr. Anjali Geethadevi

Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/158612

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)